Cytokinetics Teases Q2 ACACIA-HCM Catalyst as MYQORZO Launch Gains Momentum at Leerink Conference [Yahoo! Finance]
Cytokinetics, Incorporated (CYTK)
Last cytokinetics, incorporated earnings: 3/3 04:00 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.cytokinetics.com/investor-overview
Company Research
Source: Yahoo! Finance
MYQORZO 's label and create a “halo effect” for the oHCM launch; phase 2 dosing showed ~85% of patients reached the highest doses with low interruption rates (~3–5%). MYQORZO launch momentum: approved in the U.S., Europe and China, with ~125 U.S. cardiovascular account specialists deployed, 700 REMS-certified prescribers, 90% cardiology awareness, and early patients largely treatment-naive. Cytokinetics began the year with $1.2 billion in cash to fund the U.S. launch and European expansion (Germany planned in Q2 with pricing ~15–20% of U.S.), while advancing heart-failure programs including COMET-HF (readout in ~2 years). Interested in Cytokinetics, Incorporated? Here are five stocks we like better. Analysts Think There's Still Time to Get in on Edgewise, Up 332% Cytokinetics (NASDAQ:CYTK) used its presentation at the Leerink Global Healthcare Conference to outline its transition from a long-running research-focused company into a commercial-stage cardiovascular drug develop
Show less
Read more
Impact Snapshot
Event Time:
CYTK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CYTK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CYTK alerts
High impacting Cytokinetics, Incorporated news events
Weekly update
A roundup of the hottest topics
CYTK
News
- Assessing Cytokinetics (CYTK) Valuation After New MYQORZO Trial Data And Safety Outcomes [Yahoo! Finance]Yahoo! Finance
- Cytokinetics Announces Four Presentations at the American College of Cardiology Annual Scientific Session & Expo [Yahoo! Finance]Yahoo! Finance
- Cytokinetics Announces Four Presentations at the American College of Cardiology Annual Scientific Session & ExpoGlobeNewswire
- Cytokinetics Highlights Early MYQORZO Momentum, Eyes Q2 nHCM Phase 3 Catalyst at Barclays Confab [Yahoo! Finance]Yahoo! Finance
- Cytokinetics Teases Q2 Phase 3 ACACIA-HCM Readout as Myqorzo Launch Gains Traction at Citi Conference [Yahoo! Finance]Yahoo! Finance
CYTK
Earnings
- 2/24/26 - Miss
CYTK
Sec Filings
- 3/16/26 - Form 4
- 3/16/26 - Form 144
- 3/10/26 - Form 4
- CYTK's page on the SEC website